FIGURE 5.

Corticosteroids did not alter AIM2-dependent TGF-β release from exacerbated COPD-derived PBMCs. (A) AIM2 triggered with Poly dA:dT (1 μg/ml), significantly increased the release of TGF-β after 24 h of treatment from exacerbated COPD-derived PBMCs. (B) Dexamethasone (DEX, 0.1 ng/ml and 1 ng/ml) treatment, in the presence of Poly dA:dT, did not alter TGF-β release. Similarly, no differences were observed when exacerbated COPD-derived PBMCs were treated with Indomethacin (Indo, 3.5 μg/ml) in the presence or absence of Poly dA:dT (C). Data are represented as median ± interquartile range (n = 14). Statistically significant differences were determined by ONE-way ANOVA followed by Dunn’s post–test.